Skip to main content
ABVC BIOPHARMA, INC. logo

ABVC BIOPHARMA, INC. — Investor Relations & Filings

Ticker · ABVC ISIN · US00091F1066 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2020-11-17 Interim / Quarterly Rep…
Country US United States of America
Listing US ABVC

About ABVC BIOPHARMA, INC.

https://abvcpharma.com/

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes drugs and medical devices to address unmet medical needs. The company focuses on advancing a pipeline of botanical, plant-based pharmaceuticals and medical technologies sourced from research institutions. Its therapeutic areas of focus include oncology, ophthalmology, and central nervous system disorders such as major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD). Key products in development include Vitargus®, a biodegradable vitreous substitute for eye surgery, and botanical drug candidates for MDD and ADHD. Additionally, its subsidiary, BioKey, Inc., offers contract development and manufacturing services for nutritional and pharmaceutical products.

Recent filings

Filing Released Lang Actions
QUARTERLY REPORT
Interim / Quarterly Report Q3 2020
2020-11-17 English
NOTIFICATION OF LATE FILING
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the registrant is unable to file its Quarterly Report on Form 10-Q for the period ended September 30, 2020 within the prescribed time period and requests additional time. The document does not contain the actual financial statements or substantive financial data of the 10-Q report but is rather a notification about the delay in filing that report. According to the rules, such a notification is not the report itself but an announcement related to the filing status. Therefore, this document should be classified as a Regulatory Filing (RNS), which is the fallback category for filings that do not fit other specific categories and includes officer certifications, attestations, and notifications of filing delays.
2020-11-16 English
CURRENT REPORT
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 5, 2020, reporting the entry into a material definitive agreement involving a convertible promissory note issuance. It details the terms of the note and references exhibits for the full agreements. The content focuses on a financing transaction and creation of a direct financial obligation. This matches the description of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities. The document is not a full financial report, earnings release, or management discussion, but a regulatory announcement of a financing event.
2020-11-05 English
CURRENT REPORT
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 6, 2020, reporting the closing of exchange agreements involving issuance of common stock and warrants. It details a financing transaction and issuance of securities exempt from registration. The content focuses on capital raising and financing activities rather than financial results, management changes, or other report types. The document length is 4595 characters, which is short but contains substantive information about financing transactions, not just an announcement or certification. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-10-06 English
QUARTERLY REPORT
Interim / Quarterly Report Q2 2020
2020-08-14 English
QUARTERLY REPORT
Interim / Quarterly Report Q1 2020
2020-06-29 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.